Tempus AI drops after reporting better-than-expected Q1 results
Cancer diagnostics company and retail shareholder favorite Tempus AI reported better-than-expected Q1 adjusted EBITDA, earnings, and sales numbers late Tuesday, but the stock still slumped in the after-hours session.
The company reported:
Q1 revenue of $348.1 million vs. FactSet’s expectation of $345.4 million.
An adjusted loss per share of $0.13 vs. the $0.20 loss estimated.
Adjusted EBITDA of -$2.83 million vs. expectations for -$4.95 million, per FactSet.
Since going public nearly two years ago, Tempus has been a volatile stock that has both doubled — and cratered — on multiple occasions. That spectacle has at times captured the attention of retail traders who’ve tried to ride the waves.
The surf has been bad lately, with the shares down about 8% so far this year, and roughly 50% from the record high on October 8, 2025.